Oncogenic activation of synuclein contributes to the cancer development by promoting tumor cell survival via activation of JNK/caspase apoptosis pathway and ERK, and by providing resistance to certain chemotherapeutic drugs [56], suggesting synuclein as a new therapeutic target for future treatment to overcome resistance to certain chemotherapeutic. The gene discussed is SNCA; the disease is neoplasm.